Table 3.
Response and relapse outcomes in trials assessing CD19 CAR-T therapy with 4-1BB/CD3ζ co-stimulatory domains in B-cell acute lymphoblastic leukemia with potential bridging to allogeneic hematopoietic cell transplantation.
| Maude et al. (60) | Pan et al. (61) | Gardner et al. (62) | Maude et al. (63) | Hay et al. (64) | Jiang et al. (65) | Frey et al. (66) | |
|---|---|---|---|---|---|---|---|
| Patients, n | 30 | 51 | 45 | 75 | 53 | 58 | 35 |
| Age Category | Pediatric and YA (25), Adult (5) | Pediatric, YA, and Adult | Pediatric and YA | Pediatric and YA | Adult | Pediatric, YA, and Adult | Adult |
| Median follow-up, mo | 7 | NA | 9.6 | 13.1 | 30.9 | 7.7 | 13 |
| Prior allo-HCT, % | 60 | 0 | 62 | 61 | 43 | 5 | 37 |
| CR/CRi(MRD-), % | 90 (77) | 86(81) | 89 (89) | 81(81) | 85 (85) | 88 (81) | 69 (57) |
| Allo-HCT post-CR,% | 11 | 60 | 28 | 13 | 40 | 45 | 38 |
| Relapse after CR: overall/after allo-HCT % | 26/0 | 24/7 | 45/18 | 32/NA (50% relapse-free, 50% unknown after allo-HCT) | 49/17 | 38/9 | NA (Landmark analysis for EFS p=0.03) |
Allo-HCT, allogeneic hematopoietic cell transplantation; CR, complete remissions; MRD, minimal residual disease; NA, not available; YA, young adults.